Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01131104 · ClinicalTrials.gov registry record
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 345
- Enrollment target
NCT01131104 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 345 participants.
The verdict
NCT01131104 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 345 participants
- Enrollment target
Study Summary
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION) in males. Subjects with newly diagnosed NAION will be asked via a structured questionnaire about their use of PDE5 inhibitors and other risk factors prior to the onset of their vision loss.
Interventions
- DRUG PDE5 Inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01131104
The ClinicalTrials.gov registry entry for NCT01131104 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PDE5 Inhibitors is the first listed.
NCT01131104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01131104 about?
NCT01131104 is a clinical study titled "A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors". Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION) in males. Subjec...
What is the current status of trial NCT01131104?
This trial is currently completed. The enrollment target is 345 participants. The study started on 2010-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01131104?
The interventions under investigation include: PDE5 Inhibitors (DRUG).
Who is sponsoring clinical trial NCT01131104?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.